Results overview: Found 5 records in 0.02 seconds.
Articles, 3 records found
Research literature, 2 records found
Articles 3 records found  
1.
23 p, 1.8 MB Establishing Imaging Biomarkers of Host Immune System Efficacy during Glioblastoma Therapy Response : challenges, Obstacles and Future Perspectives / Candiota Silveira, Ana Paula (Universitat Autònoma de Barcelona) ; Arús i Caraltó, Carles (Universitat Autònoma de Barcelona)
This hypothesis proposal addresses three major questions: (1) Why do we need imaging biomarkers for assessing the efficacy of immune system participation in glioblastoma therapy response? (2) Why are they not available yet? and (3) How can we produce them? We summarize the literature data supporting the claim that the immune system is behind the efficacy of most successful glioblastoma therapies but, unfortunately, there are no current short-term imaging biomarkers of its activity. [...]
2022 - 10.3390/metabo12030243
Metabolites, Vol. 12 Núm. 3 (2022) , p. 243  
2.
19 p, 1.3 MB Immune system-related changes in preclinical GL261 glioblastoma under TMZ treatment : Explaining MRSI-based nosological imaging findings with RT-PCR analyses / Calero-Perez, Pilar (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Wu, Shuang (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Arús i Caraltó, Carles (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ; Candiota Silveira, Ana Paula (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")
Glioblastomas (GB) are brain tumours with poor prognosis even after aggressive therapy. Previous work suggests that magnetic resonance spectroscopic imaging (MRSI) could act as a biomarker of efficient immune system attack onto GB, presenting oscillatory changes. [...]
2021 - 10.3390/cancers13112663
Cancers, Vol. 13, Issue 11 (June 2021) , art. 2663  
3.
24 p, 3.3 MB Anti-PD-1 immunotherapy in preclinical GL261 glioblastoma : influence of therapeutic parameters and noninvasive response biomarker assessment with MRSI-based approaches / Wu, Shuang (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Calero-Perez, Pilar (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ; Arús i Caraltó, Carles (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Candiota Silveira, Ana Paula (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")
Glioblastomas (GBs) are malignant brain tumours with poor prognosis even after aggressive therapy. Programmed cell death-1 (PD-1) immune checkpoint blockade is a promising strategy in many types of cancer, but its therapeutic effects in GB remain low and associated with immune infiltration. [...]
2020 - 10.3390/ijms21228775
International journal of molecular sciences, Vol. 21, Issue 22 (November 2020) , art. 8775  

Research literature 2 records found  
1.
187 p, 10.4 MB On the road to improve glioblastoma therapy follow-up. Immune microenvironment : what is behind the MRSI-based nosological images? / Calero Pérez, Mº Pilar ; Arús i Caraltó, Carles, dir. ; Candiota Silveira, Ana Paula, dir.
El glioblastoma (GB) és un tumor cerebral agressiu amb escassa supervivència. Calen amb urgència millores tant en les estratègies terapèutiques com de seguiment. Nosaltres hem descrit un patró oscil·latori de resposta a la temozolomida (TMZ) detectat a través d'enfocaments d'aprenentatge automàtic basats en imatges espectroscòpiques de ressonància magnètica (MRSI) en tractar ratolins C57BL/6j portadors de tumors GL261 amb el cronograma metro el sistema immunitari (IMS), que consisteix en una administració de TMZ cada 6 dies. [...]
El glioblastoma (GB) es un tumor cerebral agresivo con escasa supervivencia. Se necesitan con urgencia mejoras tanto en las estrategias terapéuticas como de seguimiento. Nosotros describimos un patrón oscilatorio de respuesta a la temozolomida (TMZ) detectado a través de enfoques de aprendizaje automático basados en imágenes espectroscópicas de resonancia magnética (MRSI) al tratar ratones C57BL/6j portadores de tumores GL261 con el cronograma metronómico de mejora inmunológica respetuoso con el sistema inmunitario (IMS), que consiste en una administración de TMZ cada 6 días. [...]
Glioblastoma (GB) is an aggressive brain tumour with poor survival. Improvements in both therapeutic and follow-up strategies are urgently needed. In this work, we described an oscillatory pattern of response to Temozolomide (TMZ) detected through magnetic resonance spectroscopic imaging (MRSI)-based machine learning approaches when treating GL261 GB tumour-bearing C57BL/6j mice with the immune respectful Immune-Enhancing Metronomic Schedule (IMS), that consists in an every 6-days TMZ administration. [...]

2022  
2.
1 p, 172.6 KB MRI-MRSI-GL261 mice / Ortega-Martorell, Sandra (Liverpool John Moores University. Department of Applied Mathematics) ; Candiota Silveira, Ana Paula (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ; Thomson, Ryan (Liverpool John Moores University. Department of Applied Mathematics) ; Julià Sapé, Ma. Margarita (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ; Olier, Iván (Liverpool John Moores University. Department of Applied Mathematics) ; Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular
MRI/MRSI data from GL261 tumor-bearing mice, from Bruker vendor.
Universitat Autònoma de Barcelona 2017 - 10.5565/ddd.uab.cat/201551
2 documents

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.